HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

AAPG

Ascentage Pharma Group International ADR

Last Close
Mar 14 • 04:00PM ET
19.00
Dollar change
+0.37
Percentage change
1.99 		%
Healthcare • Biotechnology • China • NASD
Scroll to Statements
Index- P/E- EPS (ttm)-0.70 Insider Own- Shs Outstand52.23M Perf Week-4.67%
Market Cap1.65B Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month6.44%
Income-49.71M PEG- EPS next Q- Inst Own- Short Float- Perf Quarter-
Sales125.11M P/S13.16 EPS this Y- Inst Trans31.61% Short Ratio0.84 Perf Half Y-
Book/sh1.35 P/B14.09 EPS next Y- ROA-11.99% Short Interest0.14M Perf Year-
Cash/sh1.75 P/C10.87 EPS next 5Y- ROE-53.26% 52W Range16.50 - 21.40 Perf YTD9.32%
Dividend Est.- P/FCF- EPS past 5Y-11.77% ROI-20.79% 52W High-11.21% Beta-
Dividend TTM- Quick Ratio1.83 Sales past 5Y186.51% Gross Margin87.26% 52W Low15.15% ATR (14)0.85
Dividend Ex-Date- Current Ratio1.84 EPS Y/Y TTM63.29% Oper. Margin-37.93% RSI (14)51.31 Volatility3.68% 4.10%
Employees583 Debt/Eq2.22 Sales Y/Y TTM239.00% Profit Margin-39.73% Recom- Target Price-
Option/ShortNo / Yes LT Debt/Eq1.27 EPS Q/Q- Payout- Rel Volume0.14 Prev Close18.63
Sales Surprise- EPS Surprise- Sales Q/Q- EarningsMar 27 BMO Avg Volume168.12K Price19.00
SMA20-1.82% SMA501.32% SMA2001.32% Trades Volume24,359 Change1.99%
Mar-12-25 08:46AM
Ascentage Pharma to Report Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025
(GlobeNewswire)
Mar-06-25 05:18PM
Ascentage Secures Third Breakthrough Therapy for Ph+ ALL Treatment
(Exec Edge)
Mar-05-25 06:00PM
Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
(GlobeNewswire)
Feb-07-25 08:24AM
Ascentage Pharma Announces Partial Exercise of Underwriters' Option to Purchase Additional American Depositary Shares
(GlobeNewswire)
Jan-28-25 04:01PM
Ascentage Pharma Announces Closing of U.S. Initial Public Offering
(GlobeNewswire)
Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • help • privacy • do not sell my data
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.